July 2007Issue 402


Thailand pharma

Patent busting

Getting up Big Pharma’s nose in order to save lives

Demanding fair treatment: protestors outside the US emabassy in Bangkok, May 2007.

Demanding fair treatment: protestors outside the US emabassy in Bangkok, May 2007. Adrees Latif / Reuters


Until he was appointed Minister of Public Health last October, Mongkol na Songkla was known among sections of Thailand’s medical community for his work among the poor. He had spent over 10 years as a doctor healing patients in the country’s remote north and northeast provinces, where poverty abounds. And this experience informs the way he has approached his new job, as a defiant champion for sick people. His mission: to secure affordable generic drugs for patients desperately in need of treatment for HIV/AIDS and heart disease.

By May, the success of his drive was winning praise across the world. His list of admirers included former US President Bill Clinton, the Government of Brazil and, most recently, the public health officials who endorsed Bangkok’s fight for cheaper generic drugs at the World Health Assembly in Geneva. Most vocal have been a growing chorus of grassroots and civil society groups who have come to the defence of Thailand by mounting boycotts of Big Pharma and concerted media campaigns. They see Bangkok’s achievement in the same light as some do revolutions: it has the potential to reshape the global public health landscape as we know it – in this case, the poor in the South being denied essential drugs by the pharmaceutical giants in the North.

Since late last year Thailand has invoked a clause in the rules of the World Trade Organization (WTO) called ‘compulsory licences’. This feature grants developing countries the flexibility to break patents on drugs produced by Big Pharma when faced with a national health crisis. Until now, developing countries had been forced to stay clear of this public health option due to pressure from economic powerhouses like the United States. History, though, is replete with rich nations doing otherwise; most recently, when the West forced the Swiss producer of a drug to counter the deadly avian influenza to give up its patent so that generic alternatives could be produced.

The pharmaceutical giants targeted in Bangkok’s ground-breaking attempt are Abbott, which produces the anti-retroviral (ARV) drugs Kaletra and Aluvia; Merck Sharp and Dhome, which produces the ARV Efavirenz; and Sanofi-Aventis, which holds the patent for Palvis, a blood-thinner. Abbott tried to force Thailand to backtrack by refusing to register seven new drugs there, including treatments for HIV, kidney disease and blood clots. A hostile Thai-bashing campaign by pro-pharma lobbies ensued. Even the US Government got into the act, placing Thailand on a watchlist of countries that violated intellectual property rights.

Yet Bangkok has not blinked. It believes that the power of the pharmaceutical lobby to secure profits over public health is out of step with WTO provisions for the developing world. Washington, for all its tough talk, said as much in early May. ‘While the US acknowledges a country’s ability to issue such licences in accordance with WTO rules, the lack of transparency and due process exhibited in Thailand represents a serious concern,’ stated a report by the US Trade Representative’s Office.

Boripat Dornmon, a 40-year-old who has been living with HIV for 11 years, has reason to feel more hopeful. Voicing a sentiment that the other 600,000 Thais infected with the killer disease will also share, he says: ‘We need the new, cheap drugs to live longer.’

Marwaan Macan-Markar




also by...
THIS AUTHOR

Write vs Wrong
Defiant public blitzes junta with letters

Language Tools
Powered by Ultralingua

Join over 10,000 people just like you. Get e-mail updates about new content, issue alerts, contests, and more!

other articles
FROM THIS ISSUE

Burundi
A small landlocked state in central Africa, sandwiched between its vast neighbours Tanzania and Democratic Republic of Congo, Burundi has suffered as much from ethnic conflict as its other (equally tiny) neighbour, Rwanda. Yet while the 1993 Rwandan genocide continues to commandeer international attention, Burundi’s travails tend to slip under the radar.

Of robbers and plants
Economic crunch in Mauritius

Edible Earth
In search of bright ideas, David Ransom begins by learning some very basic lessons about how to design a more sustainable, permanent culture.

The ethical heart of permaculture
Maddy Harland outlines the principles that make it beat.

The Islamophobia debate
When is it fair to criticize Islam and when is it not?

more articles
ON RELATED TOPICS

Polyp's Big Bad World – September 2005
Two faces of wanton murder, as seen by Polyp.

More depressing news
According to the World Health Organization, depression will be the second most debilitating disease in the world by 2020.

Invasion of the frog–snatchers
US bioprospecters are cashing in on Ecuador's natural resources prompting calls for regulation and compensation.

Snapshots from shantytown
A photo essay of squatter life.

recently
IN THIS COLUMN

Striking out
Nike workers in Vietnam go on strike

Bullshit in a bottle
say hello to water called Ethos

Scared of a star
West Papua’s push for independence

Fossil foolery
Fossil Fools Day

Who is Harald?
Climate negotiations

Teeny tiny terror
Nanotechnology






Voices from the margins:

Multimedia: video, podcasts, and more.